HRP20150049T1 - Derivati oksazolil-metiletera kao agonisti alx-receptora - Google Patents
Derivati oksazolil-metiletera kao agonisti alx-receptora Download PDFInfo
- Publication number
- HRP20150049T1 HRP20150049T1 HRP20150049AT HRP20150049T HRP20150049T1 HR P20150049 T1 HRP20150049 T1 HR P20150049T1 HR P20150049A T HRP20150049A T HR P20150049AT HR P20150049 T HRP20150049 T HR P20150049T HR P20150049 T1 HRP20150049 T1 HR P20150049T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- compound
- oxazol
- triazol
- carboxamide
- Prior art date
Links
- ZLOJSLIXCHGODY-UHFFFAOYSA-N 2-(1,3-oxazol-2-ylmethoxymethyl)-1,3-oxazole Chemical class N=1C=COC=1COCC1=NC=CO1 ZLOJSLIXCHGODY-UHFFFAOYSA-N 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- VAELWSLNTRVXQS-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC=N1 VAELWSLNTRVXQS-UHFFFAOYSA-N 0.000 claims 3
- 206010027654 Allergic conditions Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 206010038997 Retroviral infections Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 230000008105 immune reaction Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- -1 methoxy, trifluoroethyl Chemical group 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- KICLUPYLEMTGRA-UHFFFAOYSA-N 2-cyclopropyl-n-[2-[[4-(methoxymethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide Chemical compound COCC1=COC(CN2N=C(NC(=O)C3=C(OC(=N3)C3CC3)C=3C=C(C)C=CC=3)C=N2)=N1 KICLUPYLEMTGRA-UHFFFAOYSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- JSJMTFMLKUQDNK-UHFFFAOYSA-N n-[2-[[4-(2-methoxypropan-2-yl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide Chemical compound COC(C)(C)C1=COC(CN2N=C(NC(=O)C3=C(OC(C)=N3)C=3C=C(C)C=CC=3)C=N2)=N1 JSJMTFMLKUQDNK-UHFFFAOYSA-N 0.000 claims 1
- WOVGNQPABJPTNQ-UHFFFAOYSA-N n-[2-[[4-(ethoxymethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-2-methyl-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide Chemical compound CCOCC1=COC(CN2N=C(NC(=O)C3=C(OC(C)=N3)C=3C=C(C)C=CC=3)C=N2)=N1 WOVGNQPABJPTNQ-UHFFFAOYSA-N 0.000 claims 1
- QFOBKROZSQBGMI-UHFFFAOYSA-N n-[2-[[4-(ethoxymethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-5-phenyl-1,3-oxazole-4-carboxamide Chemical compound CCOCC1=COC(CN2N=C(NC(=O)C3=C(OC=N3)C=3C=CC=CC=3)C=N2)=N1 QFOBKROZSQBGMI-UHFFFAOYSA-N 0.000 claims 1
- FWLUBQQLSKAVSB-UHFFFAOYSA-N n-[2-[[4-(methoxymethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-5-(3-methylphenyl)-1,3-oxazole-4-carboxamide Chemical compound COCC1=COC(CN2N=C(NC(=O)C3=C(OC=N3)C=3C=C(C)C=CC=3)C=N2)=N1 FWLUBQQLSKAVSB-UHFFFAOYSA-N 0.000 claims 1
- UGFJIELPBKMWQL-UHFFFAOYSA-N n-[2-[[4-(methoxymethyl)-1,3-oxazol-2-yl]methyl]triazol-4-yl]-5-phenyl-1,3-oxazole-4-carboxamide Chemical compound COCC1=COC(CN2N=C(NC(=O)C3=C(OC=N3)C=3C=CC=CC=3)C=N2)=N1 UGFJIELPBKMWQL-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (15)
1. Spoj, naznačeno time, da ima formulu (I),
[image]
gdje
R1 predstavlja fenil koji je nesupstituiran ili je mono-supstituiran sa sljedećima: halogen, (C1-C4)alkil, (C1-C4)alkoksi, (C1-C2)fluoroalkil ili (C1-C2)fluoroalkoksi;
R2 predstavlja vodik, metil ili ciklopropil;
R3 i R4 su isti i predstavljaju vodik ili metil; i
R5 predstavlja (C1-C2)alkil;
ili sol takvoga spoja.
2. Spoj formule (I) prema zahtjevu 1, naznačen time, da
R1 predstavlja fenil koji je nesupstituiran ili je mono-supstituiran sa sljedećima: fluor, klor, metil, metoksi, tri fluor om etil ili trifluorometoksi;
R2 predstavlja vodik ili metil;
R3 i R4 su isti i predstavljaju vodik ili metil; i
R5 predstavlja metil;
ili sol takvoga spoja.
3. Spoj formule (I) prema bilo kojem zahtjevu 1 ili 2, naznačen time, da
R1 predstavlja fenil koji je nesupstituiran ili je mono-supstituiran sa sljedećima: fluor, klor, metil, metoksi, trifluorometil ili trifluorometoksi; ili sol takvoga spoja.
4. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 3, naznačen time, da u slučaju da R1 predstavlja mono-supstituiranu fenil-skupinu, spomenuta fenil-skupina se supstituira na meta-poziciji; ili sol takvoga spoja.
5. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 4, naznačen time, da R2 predstavlja vodik ili metil; ili sol takvoga spoja.
6. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 4, naznačen time, da R2 predstavlja metil; ili sol takvoga spoja.
7. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 6, naznačen time, da R3 i R4 oba predstavljaju vodik; ili sol takvoga spoja.
8. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 6, naznačen time, da R3 i R4 oba predstavljaju metil; ili sol takvoga spoja.
9. 9, Spoj formule (I) prema bilo kojem zahtjevu od 1 do 8, naznačen time, da R5 predstavlja metil; ili sol takvoga spoja.
10. Spoj formule (I) prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
N-(2-((4-(2-metoksipropan-2-il)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-2-metil-5-(m-tolil)oksazol-4-karboksamid;
N-(2-((4-(2-metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-2-metil-5-(m-tolil)oksazol-4-karboksamid;
N-(2-((4-(2-metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-2-metil-5-feniloksazol-4-karboksamid;
5-((3-klorofenil)-N-(2-((4-(metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-2-metiloksazol-4-karboksamid;
N-(2-((4-(2-metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-2-metil-5-(3-(trifluorometil)fenil)oksazol-4-karboksamid;
5-((3-klorofenil)-N-(2-((4-(metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)oksazol-4-karboksamid;
N-(2-((4-(2-metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-5-(3-metoksifenil)oksazol-4-karboksamid;
N-(2-((4-(2-metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-5-(3-metoksifenil)-2-metiloksazol-4-karboksamid;
5-((3-fluorofenil)-N-(2-((4-(metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-2-metiloksazol-4-karboksamid;
N-(2-((4-(metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-5-(m-tolil)oksazol-4-karboksamid;
N-(2-((4-(metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-2-metil-5-(3-(trifluorometoksi)fenil)oksazol-4-karboksamid;
2-ciklopropil-N-(2-((4-(metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-5-(m-tolil)oksazol-4-karboksamid; i
N-(2-((4-(metoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-5-feniloksazol-4-karboksamid;
11. Spoj formule (I) prema zahtjevu 1, naznačen time, daje odabran iz skupine koju čine:
N-(2-((4-(etoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-2-metil-5-(m-tolil)oksazol-4-karboksamid;
N-(2-((4-(etoksimetil)oksazol-2-il)metil)-2H-1,2,3-triazol-4-il)-5-feniloksazol-4-karboksamid;
12. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 11, ili njegova farmaceutski prikladna sol, naznačen time, da se upotrebljava kao lijek.
13. Farmaceutski sastav, naznačen time, da kao djelotvorni sastojak, obuhvaća spoj formule I prema bilo kojem od zahtjeva 1 do 11, ili njegovu farmaceutski prikladnu sol, te najmanje jedno terapeutski inertno pomoćno sredstvo.
14. Uporaba spoja formule (I) prema bilo kojem zahtjevu od 1 do 11, ili njegove farmaceutski prikladne soli, naznačena time, da je za proizvodnju lijeka za prevenciju ili liječenje bolesti odabrane od sljedećih: upalne bolesti, opstrukcijske bolesti dišnih puteva, alergijska stanja, retrovirusne infekcije povezane s HIV-om, kardiovaskularni poremećaji, neurološka zapaljenja, neurološki poremećaji, bolovi, bolesti posredovane prionima i poremećaji posredovani amiloidima; te za modulaciju imunoloških reakcija.
15. Spoj formule (I) prema bilo kojem zahtjevu od 1 do 11, ili njegova farmaceutski prikladna sol, naznačen/a time, da se upotrebljava za prevenciju ili liječenje bolesti odabrane od sljedećih: upalne bolesti, opstrukcijske bolesti dišnih puteva, alergijska stanja, retrovirusne infekcije povezane s HIV-om, kardiovaskularni poremećaji, neurološka zapaljenja, neurološki poremećaji, bolovi, bolesti posredovane prionima i poremećaji posredovani amiloidima; te za modulaciju imunoloških reakcija.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2010055616 | 2010-12-07 | ||
| EP11804810.7A EP2649068B1 (en) | 2010-12-07 | 2011-12-06 | Oxazolyl-methylether derivatives as alx receptor agonists |
| PCT/IB2011/055487 WO2012077049A1 (en) | 2010-12-07 | 2011-12-06 | Oxazolyl-methylether derivatives as alx receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150049T1 true HRP20150049T1 (hr) | 2015-02-27 |
Family
ID=45444667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150049AT HRP20150049T1 (hr) | 2010-12-07 | 2015-01-13 | Derivati oksazolil-metiletera kao agonisti alx-receptora |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8846733B2 (hr) |
| EP (1) | EP2649068B1 (hr) |
| JP (1) | JP5923107B2 (hr) |
| KR (1) | KR101864463B1 (hr) |
| CN (1) | CN103261194B (hr) |
| AR (1) | AR084173A1 (hr) |
| AU (1) | AU2011340146B2 (hr) |
| CA (1) | CA2816376C (hr) |
| CY (1) | CY1116004T1 (hr) |
| DK (1) | DK2649068T3 (hr) |
| ES (1) | ES2526132T3 (hr) |
| HR (1) | HRP20150049T1 (hr) |
| MX (1) | MX2013006418A (hr) |
| PL (1) | PL2649068T3 (hr) |
| PT (1) | PT2649068E (hr) |
| RU (1) | RU2588567C2 (hr) |
| SI (1) | SI2649068T1 (hr) |
| TW (1) | TWI523853B (hr) |
| WO (1) | WO2012077049A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2640699B1 (en) | 2010-11-17 | 2015-10-07 | Actelion Pharmaceuticals Ltd. | Bridged spiro[2,4]heptane ester derivatives |
| JP6101788B2 (ja) | 2012-05-16 | 2017-03-22 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ＡＬＸ受容体アゴニストとしての１−（ｐ−トリル）シクロプロピル置換架橋スピロ［２．４］ヘプタン誘導体 |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| CA2915757A1 (en) | 2013-07-18 | 2015-01-22 | Actelion Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| PE20161206A1 (es) | 2013-11-28 | 2016-11-05 | Kyorin Seiyaku Kk | Derivado de urea o sal farmacologicamente aceptable del mismo |
| US10858314B2 (en) | 2015-05-27 | 2020-12-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| TW201702226A (zh) | 2015-05-27 | 2017-01-16 | 杏林製藥股份有限公司 | 尿素衍生物或其醫藥上可接受鹽 |
| US11439615B2 (en) | 2017-03-09 | 2022-09-13 | University Health Network | Lipoxin and lipoxin analogue mediated neuroprotection and treatments |
| SG11202008504SA (en) | 2018-03-05 | 2020-10-29 | Bristol Myers Squibb Co | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62234018A (ja) | 1986-04-02 | 1987-10-14 | Rooto Seiyaku Kk | 糖尿病併発症治療剤 |
| WO2002024656A1 (fr) | 2000-09-22 | 2002-03-28 | Nihon Nohyaku Co., Ltd. | Derives de n-(4-pyrazolyl amide, produits chimiques pour utilisation agricole et horticole et applications desdits derives |
| AU2003214249A1 (en) | 2002-04-03 | 2003-10-13 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| JP2007516434A (ja) | 2003-11-07 | 2007-06-21 | アカディア ファーマシューティカルズ インコーポレイティド | リポキシン受容体ｆｐｒｌ１の、疼痛および炎症の治療に有効な化合物を識別する手段としての使用 |
| RU2006145872A (ru) * | 2004-05-25 | 2008-06-27 | Метаболекс, Инк. (Us) | Замещенные триазолы в качестве модуляторов ppar и способы их получения |
| EP1945617B1 (en) | 2005-11-03 | 2012-12-26 | Merck Sharp & Dohme Corp. | Histone deacetylase inhibitors with aryl-pyrazolyl motifs |
| BRPI0815634B1 (pt) | 2007-08-21 | 2024-01-09 | Firmenich Incorporated | Receptores t2r humanos que respondem a compostos amargos que causam gosto amargo nas composições e seus métodos de produção, bem como método de redução ou alívio do sabor amargo em uma composição, composição de alimento, bebida ou medicamento ou composição de um produto nãocomestível |
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| CA2706839C (en) | 2007-12-18 | 2015-10-20 | Actelion Pharmaceuticals Ltd | Aminotriazole derivatives as alx agonists |
| KR101724765B1 (ko) | 2009-05-18 | 2017-04-07 | 액테리온 파마슈티칼 리미티드 | Ａｌｘ 수용체 및/또는 ｆｐｒｌ2 아고니스트로서의 브릿지 스피로［2.4］헵탄 유도체 |
| CN101909306A (zh) * | 2009-06-08 | 2010-12-08 | 中兴通讯股份有限公司 | 中继站管理方法及基站 |
| RU2544862C2 (ru) | 2009-06-09 | 2015-03-20 | Актелион Фармасьютиклз Лтд | Фторированные аминотриазольные производные |
| KR20120046159A (ko) | 2009-06-12 | 2012-05-09 | 액테리온 파마슈티칼 리미티드 | Ａｌｘ 수용체 아고니스트로서의 옥사졸 및 티아졸 유도체 |
| JP2012254939A (ja) * | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
-
2011
- 2011-12-06 JP JP2013542652A patent/JP5923107B2/ja not_active Expired - Fee Related
- 2011-12-06 CN CN201180058458.7A patent/CN103261194B/zh not_active Expired - Fee Related
- 2011-12-06 ES ES11804810.7T patent/ES2526132T3/es active Active
- 2011-12-06 KR KR1020137017686A patent/KR101864463B1/ko active IP Right Grant
- 2011-12-06 PT PT118048107T patent/PT2649068E/pt unknown
- 2011-12-06 AR ARP110104559A patent/AR084173A1/es unknown
- 2011-12-06 SI SI201130348T patent/SI2649068T1/sl unknown
- 2011-12-06 CA CA2816376A patent/CA2816376C/en not_active Expired - Fee Related
- 2011-12-06 EP EP11804810.7A patent/EP2649068B1/en not_active Not-in-force
- 2011-12-06 WO PCT/IB2011/055487 patent/WO2012077049A1/en active Application Filing
- 2011-12-06 US US13/992,143 patent/US8846733B2/en not_active Expired - Fee Related
- 2011-12-06 RU RU2013130879/04A patent/RU2588567C2/ru not_active IP Right Cessation
- 2011-12-06 MX MX2013006418A patent/MX2013006418A/es active IP Right Grant
- 2011-12-06 TW TW100144916A patent/TWI523853B/zh not_active IP Right Cessation
- 2011-12-06 DK DK11804810.7T patent/DK2649068T3/en active
- 2011-12-06 AU AU2011340146A patent/AU2011340146B2/en not_active Ceased
- 2011-12-06 PL PL11804810T patent/PL2649068T3/pl unknown
-
2015
- 2015-01-13 HR HRP20150049AT patent/HRP20150049T1/hr unknown
- 2015-01-23 CY CY20151100075T patent/CY1116004T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012077049A1 (en) | 2012-06-14 |
| TWI523853B (zh) | 2016-03-01 |
| JP5923107B2 (ja) | 2016-05-24 |
| CY1116004T1 (el) | 2017-01-25 |
| US20130261159A1 (en) | 2013-10-03 |
| CA2816376C (en) | 2018-11-20 |
| SI2649068T1 (sl) | 2015-01-30 |
| AU2011340146B2 (en) | 2016-05-19 |
| PL2649068T3 (pl) | 2015-03-31 |
| RU2013130879A (ru) | 2015-01-20 |
| AR084173A1 (es) | 2013-04-24 |
| CN103261194A (zh) | 2013-08-21 |
| US8846733B2 (en) | 2014-09-30 |
| DK2649068T3 (en) | 2014-12-08 |
| ES2526132T3 (es) | 2015-01-07 |
| EP2649068A1 (en) | 2013-10-16 |
| MX2013006418A (es) | 2013-07-15 |
| PT2649068E (pt) | 2014-12-23 |
| CA2816376A1 (en) | 2012-06-14 |
| CN103261194B (zh) | 2016-02-24 |
| JP2013544878A (ja) | 2013-12-19 |
| TW201305151A (zh) | 2013-02-01 |
| EP2649068B1 (en) | 2014-10-29 |
| KR101864463B1 (ko) | 2018-06-04 |
| AU2011340146A1 (en) | 2013-07-25 |
| KR20130133240A (ko) | 2013-12-06 |
| RU2588567C2 (ru) | 2016-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150049T1 (hr) | Derivati oksazolil-metiletera kao agonisti alx-receptora | |
| HRP20210459T1 (hr) | Supstituirani derivati oksopiridina | |
| HRP20170112T1 (hr) | Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze | |
| HRP20220003T1 (hr) | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| HRP20200341T1 (hr) | Bromodomenski (bet) inhibitori | |
| HRP20110825T1 (hr) | Derivati aminotriazola kao alx agonisti | |
| HRP20170363T1 (hr) | Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret) | |
| HRP20151405T1 (hr) | Novi supstituirani kinolinski spojevi kao inhibitori reduktaze s-nitrosoglutationa | |
| JP2010534647A5 (hr) | ||
| NZ596071A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| HRP20160450T1 (hr) | Novi inhibitori reduktaze s-nitrozoglutationa | |
| JP2014502979A5 (hr) | ||
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| JP2013542937A5 (hr) | ||
| JP2016505619A5 (hr) | ||
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| JP2011529037A5 (hr) | ||
| CA2600409A1 (en) | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds | |
| RU2011153772A (ru) | Фторированные аминотриазольные производные | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| AR082458A1 (es) | Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 | |
| PE20191146A1 (es) | Inhibidores de magl | |
| JP2010510202A5 (hr) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 |